Management of anemia in patients with cancer

被引：13

作者：

Steensma D.P. ^{[1
]}

机构：

[1] Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905

来源：

Current Oncology Reports | 2004年 / 6卷 / 4期

关键词：

Erythropoietin; Darbepoetin Alfa; Intravenous Iron; Iron Sucrose; Iron Dextran;

D O I：

10.1007/s11912-004-0039-9

中图分类号：

学科分类号：

摘要：

Anemia is extremely common in patients with cancer. Low hemoglobin levels are associated with diminished quality of life and possibly decreased overall survival. Successful treatment of anemia has undeniable benefits for patients, often yielding dramatic symptomatic improvement that can be very satisfying for clinicians to observe. This review focuses on evolving issues in the management of anemia in patients suffering from cancer. Topics addressed include new evidence-based guidelines concerning the use of epoetin alfa, the evolving role of darbepoetin alfa in cancer-associated anemia, the potential for concomitant iron supplementation to maximize response to erythropoietic agents, the unresolved question of whether erythropoietin use affects survival in cancer patients, new concerns about the risk of thromboembolism in cancer patients with higher hemoglobin levels who are receiving epoetin, and possible immunosuppressive effects of blood product transfusions that may have relevance to neoplasia progression. Copyright © 2004 by Current Science Inc.

引用

页码：297 / 304

页数：7

共 54 条

[31]

Goodnough L.T., Skikne B., Brugnara C., Erythropoietin, iron, and erythropoiesis, Blood, 96, pp. 823-833, (2000)

[32]

Weiss G., Iron and anemia of chronic disease, Kidney Int., 69, SUPPL., (1999)

[33]

Finch C.A., Erythropoiesis, erythropoietin, and iron, Blood, 60, pp. 1241-1246, (1982)

[34]

Goodnough L.T., The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy, Nephrol. Dial. Transplant., 17, SUPPL. 5, pp. 14-18, (2002)

[35]

Goodnough L.T., Marcus R.E., Erythropoiesis in patients stimulated with erythropoietin: The relevance of storage iron, Vox. Sang., 75, pp. 128-133, (1998)

[36]

Price T.H., Goodnough L.T., Vogler W.R., Et al., The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: A multicenter, randomized, double-blind, controlled trial, Transfusion, 36, pp. 29-36, (1996)

[37]

Stoves J., Inglis H., Newstead C.G., A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin, Nephrol. Dial. Transplant., 16, pp. 967-974, (2001)

[38]

Olijhoek G., Megens J.G., Musto P., Et al., Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: A randomized, placebo-controlled trial, Transfusion, 41, pp. 957-963, (2001)

[39]

Macdougall I.C., Strategies for iron supplementation: Oral versus intravenous, Kidney Int., 69, SUPPL., (1999)

[40]

Fishbane S., Safety in iron management, Am. J. Kidney Dis., 41, SUPPL., pp. 18-26, (2003)

← 1 2 3 4 5 6 →